Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gerhard Puchtler"'
Autor:
Clemens Giessen, Nicolas Moosmann, Thomas Decker, M. Schulze, Sebastian Stintzing, Herbert W. Kappauf, H. Dietzfelbinger, Martina Stauch, Gerhard Puchtler, S. Klein, W. Abenhardt, Holger G. Hass, L. Fischer von Weikersthal, Daniel Oruzio, Ursula Vehling-Kaiser, Volker Heinemann, Johann Mittermüller, Christopher Haberl, Klaus Zellmann
Publikováno v:
British Journal of Cancer
Background: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxalipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0b770518b98ac96790a209da2cea95
http://europepmc.org/articles/PMC3142807
http://europepmc.org/articles/PMC3142807
Autor:
Herbert W. Kappauf, W. Abenhardt, Daniel Oruzio, S. Klein, Thomas Decker, Nicolas Moosmann, M. Schulze, Sebastian Stintzing, Martina Stauch, Volker Heinemann, Andreas Schalhorn, Herrmann Dietzfelbinger, Gerhard Puchtler, Ursula Vehling-Kaiser, Christopher Haberl, Ludwig Fischer von Weikersthal, Holger G. Hass, Andreas Jung, Johann Mittermüller, Klaus Zellmann
Publikováno v:
Journal of Clinical Oncology. 29:1050-1058
Purpose The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac0b3e73211c7bfb3f3bf24e333ed8b
https://doi.org/10.1200/jco.2010.31.1936
https://doi.org/10.1200/jco.2010.31.1936
Autor:
Dominik Paul Modest, Daniel Oruzio, Klaus Zellmann, S. Klein, Thomas Decker, Johann Mittermueller, Volker Heinemann, M. Schulze, Sebastian Stintzing, Wolfgang Abenhardt, Ruediger P. Laubender, Ludwig Fischer von Weikersthal, Hermann F. Dietzfelbinger, Gerhard Puchtler, Holger G. Hass, Martina Stauch, Ursula Vehling-Kaiser, Ulrich Mansmann, Herbert W. Kappauf, Christopher Haberl
Publikováno v:
Journal of Clinical Oncology. 30:3588-3588
3588 Background: This study investigated the impact of early tumor-shrinkage (ETS) on progression-free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated within the AIO KRK-0104-trial. ETS was previously show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c9696c66d79dc0b59051fb98948118d
https://doi.org/10.1200/jco.2012.30.15_suppl.3588
https://doi.org/10.1200/jco.2012.30.15_suppl.3588
Autor:
Herbert W. Kappauf, Klaus Zellmann, Clemens Giessen, W. Abenhardt, Daniel Oruzio, L. Fischer von Weikersthal, J. Mittermueller, Martina Stauch, M. Schulze, Sebastian Stintzing, Volker Heinemann, Gerhard Puchtler, Nicolas Moosmann, H. Dietzfelbinger, Thomas Decker, S. Klein, Holger G. Hass, Ursula Vehling-Kaiser, Christopher Haberl
Publikováno v:
Journal of Clinical Oncology. 29:3589-3589
3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58598256738f7e17659712ddc847fdca
https://doi.org/10.1200/jco.2011.29.15_suppl.3589
https://doi.org/10.1200/jco.2011.29.15_suppl.3589